CyMedica Orthopedics Inc has received FDA 510(k) clearance for e-vive, an app-controlled, data-driven muscle-activation and patient-engagement therapy designed to help patients prepare for, and then rehab after, ACL and TKR surgery.
The e-vive muscle stimulation device was engineered to address the problems associated with muscle atrophy postsurgery, which can lead to additional rehabilitation or hospital readmissions.
The app features an interface that can be operated from any smartphone, as well as embedded garment sensor technology that transfers data points to a cloud-based portal where physicians can track patient progress.
“The launch of e-vive represents a breakthrough in the treatment of muscle atrophy of the knee,” says Struan Coleman, MD, PhD Sports Medicine Surgeon at Hospital for Special Surgery and CyMedica co-founder, in a media release from the Scottsdale, Ariz-based company.
“My patients now have access to a world-class muscle activation device that not only improves their quadriceps function, but also allows me to remotely monitor the progress of their rehabilitation. Through e-vive I am able to deliver better outcomes both for my patients and for the hospitals supporting the new economics of quality based care,” he adds.
[Source(s): CyMedica Orthopedics Inc, PR Newswire]
